gsk239512 and Cognition-Disorders

gsk239512 has been researched along with Cognition-Disorders* in 1 studies

Trials

1 trial(s) available for gsk239512 and Cognition-Disorders

Article	Year
A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophrenia research, 2015, Volume: 164, Issue:1-3 This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H₃ receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7 weeks (4 weeks titration). GSK239512 was associated with a small positive effect size (ES) on the CogState Schizophrenia Battery (CSSB) Composite Score (ES=0.29, CI=-0.40, 0.99) relative to placebo (primary endpoint). GSK239512's ES on CSSB domains were generally positive or neutral except Processing Speed, which favored placebo (ES=-0.46). Effects on the MATRICS Consensus Cognitive Battery were mostly neutral or favored placebo. GSK239512 was generally well tolerated with an adverse event profile consistent with the known class pharmacology. There was no evidence of overall beneficial effects of GSK239512 for CIAS in this population. Topics: Adult; Antipsychotic Agents; Benzazepines; Cognition Disorders; Female; Histamine Antagonists; Humans; Male; Middle Aged; Neuropsychological Tests; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome; Young Adult	2015

Article

Year

A Phase II study of a histamine H₃ receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy.

Schizophrenia research, 2015, Volume: 164, Issue:1-3

This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H₃ receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7 weeks (4 weeks titration). GSK239512 was associated with a small positive effect size (ES) on the CogState Schizophrenia Battery (CSSB) Composite Score (ES=0.29, CI=-0.40, 0.99) relative to placebo (primary endpoint). GSK239512's ES on CSSB domains were generally positive or neutral except Processing Speed, which favored placebo (ES=-0.46). Effects on the MATRICS Consensus Cognitive Battery were mostly neutral or favored placebo. GSK239512 was generally well tolerated with an adverse event profile consistent with the known class pharmacology. There was no evidence of overall beneficial effects of GSK239512 for CIAS in this population.

Topics: Adult; Antipsychotic Agents; Benzazepines; Cognition Disorders; Female; Histamine Antagonists; Humans; Male; Middle Aged; Neuropsychological Tests; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome; Young Adult

2015